|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1850 K STREET, NW |
Address2 | SUITE 650 |
City | WASHINGTON |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Cambridge |
State | MA |
Zip Code | 02142 |
Country | USA |
|
5. Senate ID# 16054-12
|
||||||||
|
6. House ID# 302570000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Mary McGrane, Senior Vice President |
Date | 07/19/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 1249/S. 23, the America Invents Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
|
|
Sara |
Froelich |
|
|
|
Kay |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues
HCPCS Coding Decisions
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act
Least Costly Alternative Policy
Deficit Reduction Proposals to Joint Committee
Changes re: Medicare Part B and Average Sales Price
H.R. 2672/S. 1423, Preserving Access to Orphan Drugs Act
Medicare Secondary Payor for ESRD Services
Extension of Rebates on Medicare Part D Drugs
Performance Measures for Bone and Mineral Metabolism for ESRD Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
|
|
Sara |
Froelich |
|
|
|
Kay |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S.606/H.R. 3059 - Creating Hope Act of 2011
Prescription Drug User Fee Act Reauthorization
S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act
H.R. 1483, Drug Safety Enhancement Act
H.R. 3737, ULTRA (Unlocking Lifesaving Treatments for Rare Diseases) Act
H.R. 4132, FAST (Faster Access to Specialized Treatments) Act
Amendments to FDA Accelerated Approval Requirements
H.R. 4156, EXPERRT (Expanding and Promoting Expertise in Review of Rare Treatments) Act
H.R. 2182, GAIN (Generating Antibiotic Incentives Now) Act
S. 1734, Generating Antibiotic Incentives Now Act
Biosimilars User Fees
Biosimilars Exclusivity Period in Administration's Budget Proposals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
|
|
Sara |
Froelich |
|
|
|
Kay |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act
Excise Tax for Drugs and Biologics
Extension of R& D Tax Credit
H.R.942, American Research and Competitiveness Act
S. 1577 Greater Research Opportunities with Tax Help Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
|
|
Sara |
Froelich |
|
|
|
Kay |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act
340B Issues
Drug Shortage Issues
Drug Supply Chain Security
AHRQ Report on Enzyme Replacement Therapy for Lysosomal Storage Diseases
H.R. 2674, 340B Program Improvement Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agency for Health Care Policy & Research
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
|
|
Sara |
Froelich |
|
|
|
Kay |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2013 Budget
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011, Pub. L. 112-96
H.Con. Res. 112, Establishing the Budget for the U.S. Government for FY2013
H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary |
McGrane |
|
|
|
Sara |
Froelich |
|
|
|
Kay |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the ultimate parent of Genzyme Corporation, Sanofi Aventis, identified on Form LD-1, has an interest in the issues lobbied.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |